Toll-like receptors in cerebral ischemic inflammatory injury

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Wang, Yan Chun ^a   Lin, Sen ^b   Yang, Qing Wu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

Cerebral ischemia; Inflammation; Innate immunity; Toll like receptors (tlrs)

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; LIGAND; MEMBRANE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 12; TOLL LIKE RECEPTOR 13; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

BRAIN DAMAGE; BRAIN ISCHEMIA; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOWN REGULATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN INJURY; IMMUNOLOGY; PATHOLOGY;

ANIMALS; BRAIN INJURIES; BRAIN ISCHEMIA; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIGANDS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 80053606159     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-134     Document Type: Review

References (69)

1. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration?. Nat Rev Neurosci 2002, 3:216-227. 10.1038/nrn752, 11994753.
2. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58:253-263.
3. Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res 2006, 83:711-730. 10.1002/jnr.20767, 2440498, 16541438.
4. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease--a double-edged sword. Neuron 2002, 35:419-432. 10.1016/S0896-6273(02)00794-8, 12165466.
5. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007, 21:325-332. 10.1096/fj.06-7227rev, 3119634, 17267386.
6. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009, 68:217-226. 10.1097/NEN.0b013e3181996688, 19225414.
7. Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosi 2010, 17:6-10.
8. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69. 10.1038/nrn2038, 17180163.
9. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680. 10.1038/90609, 11477402.
10. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801. 10.1016/j.cell.2006.02.015, 16497588.
11. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384. 10.1038/ni.1863, 20404851.
12. Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, Harrington CA, Stenzel-Poore MP. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci 2009, 29:9839-9849. 10.1523/JNEUROSCI.2496-09.2009, 2946887, 19657036.
13. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009, 158:1007-1020. 10.1016/j.neuroscience.2008.07.067, 2674023, 18809468.
14. Carty M, Bowie AG. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem Pharmacol 2011, 81:825-837. 10.1016/j.bcp.2011.01.003, 21241665.
15. Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, Woodruff TM. Toll-like receptors in ischemia-reperfusion injury. Shock 2009, 32:4-16. 10.1097/SHK.0b013e318193e333, 19008778.
16. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17:1-14.
17. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364. 10.1038/nri2079, 17457343.
18. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004, 16:3-9. 10.1016/j.smim.2003.10.003, 14751757.
19. Yang QW, Li JC, Lu FL, Wen AQ, Xiang J, Zhang LL, Huang ZY, Wang JZ. Upregulated expression of toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J Cereb Blood Flow Metab 2008, 28:1588-1596. 10.1038/jcbfm.2008.50, 18523439.
20. Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S, Xiang J, Li JC, Fang CQ, Wang JZ. HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 2011, 31:593-605. 10.1038/jcbfm.2010.129, 20700129.
21. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, Lee JK. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006, 26:6413-6421. 10.1523/JNEUROSCI.3815-05.2006, 16775128.
22. Arumugam TV, Tang SC, Lathia JD, Cheng A, Mughal MR, Chigurupati S, Magnus T, Chan SL, Jo DG, Ouyang X, Fairlie DP, Granger DN, Vortmeyer A, Basta M, Mattson MP. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 2007, 104:14104-14109. 10.1073/pnas.0700506104, 1955802, 17715065.
23. Cao CX, Yang QW, Lv FL, Cui J, Fu HB, Wang JZ. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun 2007, 353:509-514. 10.1016/j.bbrc.2006.12.057, 17188246.
24. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115:1599-1608. 10.1161/CIRCULATIONAHA.106.603431, 17372179.
25. Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, Moroni F, Chiarugi A. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 2007, 103:590-603. 10.1111/j.1471-4159.2007.04788.x, 17666052.
26. Kim JB, Lim CM, Yu YM, Lee JK. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 2008, 86:1125-1131. 10.1002/jnr.21555, 17975839.
27. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ, Bendszus M, Rossetti G, Nawroth PP, Bierhaus A, Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008, 28:12023-12031. 10.1523/JNEUROSCI.2435-08.2008, 19005067.
28. Qiu J, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI, Salomone S, Moskowitz MA. Early release of HMGB1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008, 28:927-938. 10.1038/sj.jcbfm.9600582, 18000511.
29. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 2003, 100:8514-8519. 10.1073/pnas.1432609100, 166260, 12824464.
30. Yang QW, Wang JZ, Li JC, Zhou Y, Zhong Q, Lu FL, Xiang J. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 2010, 30:243-254. 10.1038/jcbfm.2009.202, 2949127, 19794402.
31. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, Rosenberg PA, Volpe JJ, Vartanian T. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 2002, 22:2478-2486.
32. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, Lathia JD, Siler DA, Chigurupati S, Ouyang X, Magnus T, Camandola S, Mattson MP. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007, 104:13798-13803. 10.1073/pnas.0702553104, 1959462, 17693552.
33. Caso JR, Pradillo JM, Hurtado O, Leza JC, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke 2008, 39:1314-1320. 10.1161/STROKEAHA.107.498212, 18309167.
34. Kilic U, Kilic E, Matter CM, Bassetti CL, Hermann DM. TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiol Dis 2008, 31:33-40. 10.1016/j.nbd.2008.03.002, 18486483.
35. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S, Krueger C, Nitsch R, Meisel A, Weber JR. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007, 190:28-33. 10.1016/j.jneuroim.2007.07.023, 17854911.
36. Ziegler G, Harhausen D, Schepers C, Hoffmann O, Rohr C, Prinz V, Konig J, Lehrach H, Nietfeld W, Trendelenburg G. TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem Biophys Res Commun 2007, 359:574-579. 10.1016/j.bbrc.2007.05.157, 17548055.
37. Abe T, Shimamura M, Jackman K, Kurinami H, Anrather J, Zhou P, Iadecola C. Key role of CD36 in Toll-like receptor 2 signaling in cerebral ischemia. Stroke 2010, 41:898-904. 10.1161/STROKEAHA.109.572552, 2950279, 20360550.
38. Ziegler G, Freyer D, Harhausen D, Khojasteh U, Nietfeld W, Trendelenburg G. Blocking TLR2 in vivo protects against accumulation of inflammatory cells and neuronal injury in experimental stroke. J Cereb Blood Flow Metab 2011, 31:757-766. 10.1038/jcbfm.2010.161, 20842165.
39. Hua F, Ma J, Ha T, Kelley JL, Kao RL, Schweitzer JB, Kalbfleisch JH, Williams DL, Li C. Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res 2009, 1262:100-108. 2722683, 19401158.
40. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, Lee DC, Ward MF, Bruchfeld AN, Wang H, Lesser ML, Church AL, Litroff AH, Sama AE, Tracey KJ. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006, 25:571-574. 10.1097/01.shk.0000209540.99176.72, 16721263.
41. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T, Sato Y, Hiraga N, Adachi N, Yoshino T, Nishibori M. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. Faseb J 2007, 21:3904-3916. 10.1096/fj.07-8770com, 17628015.
42. Weinstein JR, Koerner IP, Möller T. Microglia in ischemic brain injury. Future Neurol 2010, 5:227-246. 10.2217/fnl.10.1, 2853969, 20401171.
43. Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD, Einhaupl KM. Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain?. Stroke 1999, 30:1851-1854. 10.1161/01.STR.30.9.1851, 10471435.
44. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, Stenzel-Poore MP. Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. Stroke 2004, 35:2576-2581. 10.1161/01.STR.0000143450.04438.ae, 15375302.
45. Hickey EJ, You X, Kaimaktchiev V, Stenzel-Poore M, Ungerleider RM. Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg 2007, 133:1588-1596. 10.1016/j.jtcvs.2006.12.056, 17532961.
46. Brea D, Sobrino T, Ramos-Cabrer P, Castillo J. Inflammatory and neuroimmunomodulatory changes in acute cerebral ischemia. Cerebrovasc Dis 2009, 27(Suppl 1):48-64.
47. Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, Meller R, Simon RP, Stenzel-Poore MP. Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance. J Cereb Blood Flow Metab 2007, 27:1663-1674. 10.1038/sj.jcbfm.9600464, 17327883.
48. Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S, Akira S, Inagaki N, Nagai H, Hara H. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knockout mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 2010, 171:258-267. 10.1016/j.neuroscience.2010.08.054, 20804821.
49. Pradillo JM, Fernandez-Lopez D, Garcia-Yebenes I, Sobrado M, Hurtado O, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in neuroprotection afforded by ischemic preconditioning. J Neurochem 2009, 109:287-294. 10.1111/j.1471-4159.2009.05972.x, 19200341.
50. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, Lessov NS, Simon RP, Stenzel-Poore MP. Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2008, 28:1040-1047. 10.1038/sj.jcbfm.9600606, 3037270, 18183029.
51. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484. 10.1038/nrd2059, 16763660.
52. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997, 748:267-270. 10.1016/S0006-8993(96)01383-2, 9067475.
53. Kariko K, Weissman D, Welsh FA. Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 2004, 24:1288-1304.
54. Broad A, Kirby JA, Jones DE. Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production. Immunology 2007, 120:103-111. 2265871, 17034424.
55. Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 2002, 169:5209-5216.
56. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 2004, 21:227-239. 10.1016/j.immuni.2004.07.010, 15308103.
57. Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G, Wu X, Tao Z, Li Z, Cai X, Sun S, Xiang C, Sun B. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 2008, 9:369-377. 10.1038/ni1577, 18345001.
58. Dalpke AH, Lehner MD, Hartung T, Heeg K. Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology 2005, 116:203-212. 10.1111/j.1365-2567.2005.02211.x, 1817820, 16162269.
59. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, Hellman J. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 2007, 178:1164-1171.
60. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 1999, 5:554-559. 10.1038/8432, 10229233.
61. Liu H, Xin L, Chan BP, Teoh R, Tang BL, Tan YH. Interferon-beta administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia. Neurosci Lett 2002, 327:146-148. 10.1016/S0304-3940(02)00371-3, 12098656.
62. Veldhuis WB, Derksen JW, Floris S, Van Der Meide PH, De Vries HE, Schepers J, Vos IM, Dijkstra CD, Kappelle LJ, Nicolay K, Bar PR. Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. J Cereb Blood Flow Metab 2003, 23:1029-1039.
63. Obrenovitch TP. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev 2008, 88:211-247. 10.1152/physrev.00039.2006, 18195087.
64. Bahjat FR, Williams-Karnesky RL, Kohama SG, West GA, Doyle KP, Spector MD, Hobbs TR, Stenzel-Poore MP. Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke. J Cereb Blood Flow Metab 2011, 31:1229-1242. 10.1038/jcbfm.2011.6, 21285967.
65. Wegener S, Gottschalk B, Jovanovic V, Knab R, Fiebach JB, Schellinger PD, Kucinski T, Jungehulsing GJ, Brunecker P, Muller B, Banasik A, Amberger N, Wernecke KD, Siebler M, Rother J, Villringer A, Weih M. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke 2004, 35:616-621. 10.1161/01.STR.0000115767.17923.6A, 14963288.
66. Mori S, Liu K, Takahashi HK, Nishibori M. Therapeutic effect of anti-nucleokine monoclonal antibody on ischemic brain infarction. Yakugaku Zasshi 2009, 129:25-31. 10.1248/yakushi.129.25, 19122433.
67. Cristofaro P, Opal SM. Role of Toll-like receptors in infection and immunity: clinical implications. Drugs 2006, 66:15-29. 10.2165/00003495-200666010-00002, 16869344.
68. Guo LH, Schluesener HJ. The innate immunity of the central nervous system in chronic pain: the role of Toll-like receptors. Cell Mol Life Sci 2007, 64:1128-1136. 10.1007/s00018-007-6494-3, 17440679.
69. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004, 76:514-519. 10.1189/jlb.0304127, 15178705.